Medical
Pharmaceutical
Biopharmaceutical

Spectrum Pharmaceuticals

$9.57
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.64 (-6.27%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SPPI and other stocks, options, ETFs, and crypto commission-free!

About

Spectrum Pharmaceuticals, Inc.Common Stock, also called Spectrum Pharmaceuticals, is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA. Read More The company was founded in December 1987 and is headquartered in Henderson, NV.

Employees
235
Headquarters
Henderson, Nevada
Founded
1987
Market Cap
1.06B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.48M
High Today
$10.26
Low Today
$9.52
Open Price
$10.13
Volume
404.53K
52 Week High
$25.29
52 Week Low
$6.22

Collections

Medical
Pharmaceutical
Biopharmaceutical
Biotechnology
Health
Cancer Prevention
Technology

News

TradingNewsNowMar 22

Recent Change: Spectrum Pharmaceuticals (NASDAQ: SPPI)

Spectrum Pharmaceuticals is in the biotechnology industry and is part of the healthcare sector. The company CEO is Joseph W. Turgeon. Spectrum Pharmaceuticals Inc is a biotechnology company in the United States. It develops drugs to cure serious diseases such as chemotherapy-induced neutropenia in patients with breast cancer. Previous Intraday Trading Performance: The SPPI stock showed a previous change of 2.00% with an open at 9.95 and a close of 10.21. It reached an intraday high of 10.42 and a low of 9...

31
Seeking AlphaMar 21

Spectrum Pharmaceuticals (SPPI) To Presemt At Oppenheimer 29th Annual Healthcare Conference - Slideshow

The following slide deck was published by Spectrum Pharmaceuticals, Inc. in conjunction with this event. 1 23 Click to enlarge Notes:...

49
Seeking AlphaMar 18

Spectrum Suffers BLA Setback, But Based On Deadline, It Was For The Better

Spectrum Pharmaceuticals (SPPI) had to withdraw its Biologics License Application (BLA) of ROLONTIS after the FDA requested additional information.

65

Earnings

-$0.35
-$0.27
-$0.19
-$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 2, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.